Promising Clinical Progress and Strategic Advancements Justify Buy Rating for Vigil Neuroscience

William Blair analyst Sarah Schram has maintained their bullish stance on VIGL stock, giving a Buy rating today.

Sarah Schram’s rating is based on Vigil Neuroscience’s promising developments in their clinical trials and strategic plans for regulatory approval. The company’s Phase II IGNITE study of iluzanebart, targeting adult-onset leukoencephalopathy, is progressing well with final analysis expected in the second quarter of 2025. Encouraging interim data from this study has shown positive trends in key biomarkers, particularly in patients with advanced disease stages, which supports the potential efficacy of their treatment.
Additionally, Vigil Neuroscience is making strides with their oral small-molecule TREM2 agonist, VG-3927, as evidenced by the Phase I study results. The data revealed a significant dose-dependent reduction in soluble TREM2 levels, a favorable pharmacokinetic profile for once-daily dosing, and a manageable safety profile with only mild to moderate adverse events. These factors collectively suggest a strong potential for future success, justifying the Buy rating.

In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $11.00 price target.